ADGI ADAGIO THERAPEUTICS INC

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

H.C. Wainwright 25th Annual Global Investment Conference

Fireside Chat Date: Monday, September 11, 2023

Fireside Chat Time: 3:00 PM ET

Location: New York, NY

Morgan Stanley 21st Annual Global Healthcare Conference

Fireside Chat Date: Wednesday, September 13, 2023

Fireside Chat Time: 12:55 PM ET

Location: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the events.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit  to learn more.

Contacts:

Scott Young

(781) 208-1747

Gabriella Linville-Engler

(781) 208-0160



EN
06/09/2023

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

New Publication Demonstrates Variant-Agnostic Correlate of Protection ...

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies “A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multipl...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evalua...

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable AmericansThe LIBERTY clinical trial will evaluate comparative safety and immunology of VYD2311 versus mRNA COVID vaccine, as well as explore the safety and immunology o...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn t...

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention The educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will advance public understanding of antibodies as a centerpiece of modern wellness strategiesMedia campaign planned to launch in spring 2026 following Ms. Vonn’s closely watched and inspiring comeback season NEW HAVEN, Conn., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a partnership with renown...

January 22, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD23...

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike proteinDesign includ...

January 20, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Bus...

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in D...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch